🟢 Grifols is trading 4.1% up today, defying broader biotech sector weakness

Grifols is trading 4.1% up at $8.07 on above-average intraday strength despite a lack of clear company-specific catalysts.

• The move stands out as the broader biotech sector ETF (XBI) is down over 2% today, suggesting the gain is driven by idiosyncratic buying interest.
• There are no fresh company-specific headlines, earnings reports, FDA decisions, or major deals dated around July 28, 2026, to explain the jump.